Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsRory Shallis, MD
Assistant Professor AdjunctDownloadHi-Res Photo
About
Copy Link
Titles
Assistant Professor Adjunct
Biography
Dr. Shallis received his MD from Rutgers-Robert Wood Johnson Medical School, completed his residency training at Brown University-Rhode Island Hospital and fellowship training at Yale-New Haven Hospital.
He is focused on the care and research of patients with myeloid malignancies, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). He also participated in the K12 Calabresi Immuno-Oncology Training Program and currently participates as an investigator in several clinical trials aimed at improving the outcomes of patients with AML and MDS.
Dr. Shallis also maintains research interest in epidemiological, outcomes and effectiveness research as it pertains to the hematologic malignancies with a goal of identifying barriers to effective care and ultimately strategies to improve the outcomes of patients with these malignant diseases. Dr. Shallis conducts research with the Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center at Yale University.
Dr. Shallis has presented his research at multiple regional, national and international meetings and is a member of the National Comprehensive Cancer Network (NCCN) clinical guidelines for MDS and AML panels. He is an author on more than 75 peer-reviewed publications and book chapters, most of which as first author and has served as an ad hoc reviewer for many journals including Leukemia, Haematologica, Blood Advances, Leukemia Research, Leukemia & Lymphoma, Acta Haematologica, Hematology, Therapeutic Advances in Hematology, Expert Review of Hematology, BMC Hematology, eJHaem and Future Oncology among others.
Last Updated on November 17, 2022.
Appointments
Medical Oncology and Hematology
Assistant Professor AdjunctPrimary
Other Departments & Organizations
- Developmental Therapeutics
- Hematology
- Leukemia & Lymphoma Program
- Medical Oncology and Hematology
Education & Training
- Fellowship
- Yale - New Haven Hospital (2020)
- Internship
- Brown University - Rhode Island Hospital (2017)
- Residency
- Brown University - Rhode Island Hospital (2017)
- MD
- Rutgers University - Robert Wood Johnson Medical School (2014)
- BA
- Rutgers College, Cell Biology & Neuroscience Psychology (2010)
Research
Copy Link
Overview
Medical Research Interests
Epidemiology; Leukemia; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Myeloproliferative Disorders
ORCID
0000-0002-8542-2944
Research at a Glance
Yale Co-Authors
Frequent collaborators of Rory Shallis's published research.
Publications Timeline
A big-picture view of Rory Shallis's research output by year.
Research Interests
Research topics Rory Shallis is interested in exploring.
Jan Philipp Bewersdorf, MD, FACP
Amer Zeidan, MBBS, MD
Nikolai Podoltsev, MD, PhD
Maximilian Stahl, MD
Lourdes Mendez, MD, PhD
Rong Wang, PhD
122Publications
3,338Citations
Myelodysplastic Syndromes
Myeloproliferative Disorders
Leukemia
Myelodysplastic-Myeloproliferative Diseases
Publications
2026
Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax A Multicenter Cohort Study
Filimon S, Ghamari A, Vakilpour A, Patel R, Achar R, Akhter N, Shallis R, DeCara J, Altman J, Smith A, Matthews A, Lai C, Brunner A, Farina K, Gilman H, Neilan T, Upadhyay D, Chittams J, Anazco F, Patel A, Tremblay D, Scherrer-Crosbie M. Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax A Multicenter Cohort Study. JACC Advances 2026, 5: 102821. PMID: 42312783, PMCID: PMC13308248, DOI: 10.1016/j.jacadv.2026.102821.Peer-Reviewed Original ResearchAltmetricConceptsAcute myeloid leukemiaLeft ventricular ejection fraction reductionEjection fraction reductionStroke/transient ischemic attackMyeloid leukemiaAtrial fibrillationHeart failureCohort studyTreated with hypomethylating agentsIschemic attackMulticenter retrospective cohort studyAssociated with lower survivalRetrospective cohort studyCox proportional hazards modelsAcute coronary syndromeProportional hazards modelU.S. health care systemHypomethylating agentsPrognostic significancePrognostic implicationsVentricular tachycardia/fibrillationCardiovascular complicationsCumulative incidenceMatched CohortHealth care systemNCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.
Pollyea D, Altman J, Assi R, Bachiashvili K, Bhatt V, Fathi A, Fedorov K, Foran J, Gojo I, Goldberg A, Hall A, Jonas B, Levine M, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Patel A, Percival M, Perl A, Pettit K, Rao D, Ravandi F, Schwabkey Z, Shallis R, Stahl M, Stone R, Thota S, Uy G, Walker A, Wang E, Awotiwon A, Roth S, Stehman K. NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026. Journal Of The National Comprehensive Cancer Network 2026, 24: 222-229. PMID: 42297017, DOI: 10.6004/jnccn.2026.0028.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsAcute myeloid leukemiaClonal expansionClonal expansion of myeloid blastsTreatment of acute myeloid leukemiaNCCN Guidelines PanelNCCN Guidelines InsightsHeterogeneous hematologic malignancyResidual diseaseMyeloid blastsHematologic malignanciesPrognostic importanceAcute leukemiaMyeloid leukemiaPeripheral bloodBone marrowClinical trialsLeukemiaGuideline panelNCCNAnnual deathsTreatmentMalignancyAdultsBiological factorsMarrowComparative efficacy of antifungal prophylaxis in acute myeloid leukemia: A systematic review and meta-analysis.
Hunter C, Alhajahjeh A, Rajashekar N, Grimshaw A, Chou A, Roeder H, Eighmy W, Mendez L, Stahl M, Podoltsev N, Zeidan A, Shallis R, Bewersdorf J. Comparative efficacy of antifungal prophylaxis in acute myeloid leukemia: A systematic review and meta-analysis. Journal Of Clinical Oncology 2026, 44: e18515-e18515. DOI: 10.1200/jco.2026.44.16_suppl.e18515.Peer-Reviewed Original ResearchConceptsInvasive fungal infectionsAcute myeloid leukemiaInvasive fungal infection rateAntifungal prophylaxisDrug-drug interactionsSubgroup meta-analysisEfficacy of antifungal prophylaxisAntifungal prophylaxis useMyeloid leukemiaSecond-generation azolesAssociated with substantial mortality ratesIntensive therapyAntifungal prophylaxis agentComparative efficacyHigh riskSystematic reviewLess-intensive therapyHigh risk of infectionPosaconazoleAmphotericin BFungal infectionsProlonged neutropeniaRisk of infectionPediatric patientsCurrent guidelinesSafety and efficacy of eganelisib in adults with higher-risk myelodysplastic syndrome (HR-MDS) or relapsed/refractory (R/R) acute myeloid leukemia (AML).
Goldfinger M, Advani A, Vicente I, Garcia J, Uy G, Burgues J, Kadia T, Wang X, Arslan S, Shallis R, McMahon C, Feldman E, List A, Payton M, Borate U. Safety and efficacy of eganelisib in adults with higher-risk myelodysplastic syndrome (HR-MDS) or relapsed/refractory (R/R) acute myeloid leukemia (AML). Journal Of Clinical Oncology 2026, 44: 6507-6507. DOI: 10.1200/jco.2026.44.16_suppl.6507.Peer-Reviewed Original ResearchConceptsHigher-risk myelodysplastic syndromesPhase I studyAnti-leukemic activityR/R AMLMarrow blastsIsoform-specific inhibitorsDose levelsECOG PS <2,Evidence of clinical benefitResistance to venetoclaxBone marrow blastsHigh-risk MDSSingle agent activityGamma isoformLong duration of treatmentPoor-risk patientsPre-clinical observationsDose-dependent reductionDuration of treatmentNucleoside analoguesLong durationHematologic toxicityIPSS-RBM blastsCytogenetic responseEvaluating the cost per month of response for olutasidenib (OLU) versus ivosidenib (IVO) for patients with relapsed/refractory (R/R) mutant IDH1 (mIDH1) acute myeloid leukemia (AML).
Abaza Y, Shallis R, Thomassen A, Smare C, Pepper A, Sheppard A. Evaluating the cost per month of response for olutasidenib (OLU) versus ivosidenib (IVO) for patients with relapsed/refractory (R/R) mutant IDH1 (mIDH1) acute myeloid leukemia (AML). Journal Of Clinical Oncology 2026, 44: e18504-e18504. DOI: 10.1200/jco.2026.44.16_suppl.e18504.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMonths of CRMedian treatment durationDuration of CRAdverse eventsMonths of survivalMonths of responseTreatment durationR/R acute myeloid leukemiaIncidence of acute myeloid leukemiaPartial hematologic recoveryDuration of responseCost-effectiveness of treatment strategiesDrug costsEffectiveness of treatment strategiesMatching-adjusted indirect comparisonMonthly drug costsMean survival timePayer decision-makingComplete remissionHematologic recoveryMyeloid leukemiaIvosidenibDrug acquisitionTreatment strategiesCost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia
Ito S, Potnis K, Ng D, Patel K, Sra M, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Zeidan A, Bewersdorf J, Goshua G. Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia. Blood Red Cells & Iron 2026, 2: 100076. PMID: 42077391, PMCID: PMC13134686, DOI: 10.1016/j.brci.2026.100076.Peer-Reviewed Original ResearchThis study investigates how trainee-led teams developed updated consensus guidelines for managing peritoneal surface malignancies, demonstrating effective collaboration models for complex medical evidence synthesis.Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Mohty R, Narra R, Mims A, Hunter C, Shallis R, Kota V, Jamy O, Coltoff A, Othman T, Jonas B, Patel A, DuVall A, Foucar C, Abdelsamia M, Palmisiano N, Patel S, Curran E, Omer Z, Advani A, Atallah E, Litzow M, Badar T. Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia & Lymphoma 2026, 67: 1587-1594. PMID: 41954351, DOI: 10.1080/10428194.2026.2650679.Peer-Reviewed Original ResearchThis study investigates predictors of complete molecular response (CMR) and shows that early CMR improves relapse-free survival in Philadelphia chromosome-positive acute lymphoblastic leukemia patients.Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia.
Berton G, Bewersdorf J, Gilhodes J, Iat A, Soua A, DeAngelo D, Boussi L, Shallis R, Žučenka A, Bystrom R, Ling K, Aguirre L, Stone R, Luskin M, Garcia J, Winer E, Chen E, Wadleigh M, Mendez L, Podoltsev N, Tauveron-Jalenques U, Lanino L, Stein E, Zeidan A, Forcade E, Cluzeau T, Dumas P, Heiblig M, Devillier R, Shimony S, Goldberg A, Stahl M, Garciaz S. Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia. Haematologica 2026 PMID: 41924924, DOI: 10.3324/haematol.2025.300202.Peer-Reviewed Original ResearchAltmetricCMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML?
Komrokji R, Komrokji Z, Al Ali N, Xie Z, Chan O, Kuykendall A, Walker A, Yun S, Reynolds S, Shallis R, Lancet J, Sallman D, Padron E. CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML? Blood Neoplasia 2026, 3: 100224. PMID: 42232990, PMCID: PMC13223902, DOI: 10.1016/j.bneo.2026.100224.Peer-Reviewed Original ResearchAltmetricConceptsChronic myelomonocytic leukemiaOligomonocytic chronic myelomonocytic leukemiaMyelodysplastic syndromeRate of acute myeloid leukemia transformationMolecular International Prognostic Scoring SystemDiagnosis of chronic myelomonocytic leukemiaDysplastic CMMLAcute myeloid leukemia transformationInternational Prognostic Scoring SystemGenomic landscapePrognostic scoring systemProliferative chronic myelomonocytic leukemiaLeukemia transformationOverall survivalMyelomonocytic leukemiaHazard ratioSomatic mutationsScoring systemPatientsWorld Health OrganizationClinical measuresInternational consensusHealth OrganizationMutationsUnique entitiesMechanistic overview and suggested strategies to overcome BCL-2 inhibitor resistance in TP53-mutated acute myeloid leukemia
Iqbal U, Shallis R. Mechanistic overview and suggested strategies to overcome BCL-2 inhibitor resistance in TP53-mutated acute myeloid leukemia. Frontiers In Cell And Developmental Biology 2026, 14: 1779094. PMID: 41929632, PMCID: PMC13038875, DOI: 10.3389/fcell.2026.1779094.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTP53-mutated acute myeloid leukemiaAcute myeloid leukemiaBcl-2Executioner phase of apoptosisUpregulation of fatty acid metabolismBcl-2 familyBCL-2 dependencePhase of apoptosisMyeloid leukemiaInhibitor resistanceFamily gene mutationsBcl-2 inhibitorsFatty acid metabolismAssociated with higher ratesPopulation of patientsGenomic instabilityVenetoclax combinationsPleotropic functionsOverall survivalAcid metabolismTreatment landscapeMolecular subsetsMarrow microenvironmentLineage plasticityClinical outcomes
Academic Achievements & Community Involvement
Copy Link
Activities
activity National Comprehensive Cancer Network (NCCN) - Myelodysplastic Syndromes Guideline Panel
12/01/2020 - PresentCommitteesMemberactivity Older Adult AML Working Group - National Cancer Institute (NCI) Myeloid Precision Medicine Initiative
09/01/2020 - PresentPeer Review Groups and Grant Study SectionsMemberactivity ECOG-ACRIN Leukemia Committee
07/23/2020 - PresentCommitteesMemberactivity American Society of Hematology (ASH)
07/03/2017 - PresentProfessional OrganizationsMemberactivity American Society of Clinical Oncology (ASCO)
07/03/2017 - PresentProfessional OrganizationsMember
Honors
honor Top Overall Abstract
06/08/2020Regional AwardMyeloid Malignancies SymposiumDetailsUnited Stateshonor Hematology/Oncology Fellowship Program Research Award
06/01/2019Yale School of Medicine AwardYale Cancer CenterDetailsUnited States
News
Copy Link
News
- December 13, 2024Source: OncLive
How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD
- November 26, 2024
Yale Cancer Center to Highlight Breakthroughs in Blood Cancers and Disorders at World’s Largest Hematology Meeting
- May 01, 2024
Yale Department of Internal Medicine Faculty Promotions and Appointments (May 2024)
- March 25, 2024
Yale’s Post ASH Review
Get In Touch
Copy Link